However, DCIS-like tumoroids reduced the CD80+ M1 percentage within the obese TME: from 95% to 34.36% (Ob-PA-T, p ≤ 0.01) and from 89.9% to 39.7% (Ob-MA-T, p ≤ 0.01), while it increased the CD14+&CD80- cell percentage from 9% to 20% (Ob-PA-T, p ≤ 0.001) and from 21.16% to 45% (Ob-MA-T, p ≤ 0.001), comparing to control (Ob-PA+M1, Ob-MA+M1) (Figure 3F). This evidence concerns the gene CD80 and ductal breast carcinoma in situ.